BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The applicant GlaxoSmithKline Biologicals s.a. submitted on 4 June 2001 an application for 
Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) 
for Ambirix, in accordance with the centralised procedure falling within the scope of Part A of the 
Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur:  Dr. F. Rotblat 
Co-Rapporteur: Dr. D. Lyons 
Scientific Advice: 
The applicant did not seek scientific advice at the CPMP. 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
The procedure started on 19 June 2001. 
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP  members  on 
7 September 2001.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP 
members on 31 August 2001. 
During  the  meeting  on  16-18  October  2001  the  CPMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 18 October 2001. 
The  company  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on 
11 March 2002. 
The Rapporteur circulated the response Assessment Report on the company’s responses to the 
List of Questions to all CPMP members on 8 April 2002 (Annex 4). 
During the meeting on 28-30 May 2002 the CPMP, in the light of the overall data submitted and 
the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing Authorisation to Ambirix on 30 May 2002. 
1/1 
EMEA 2005 
 
 
 
 
 
 
 
 
 
